MEGIN Announces Three New Orders for TRIUX™ neo By Leading Institutions in Three Different Countries
HELSINKI, FINLAND (OCTOBER 9, 2019) – MEGIN is pleased to announce the sale of our fourth-generation technology, the TRIUX™ neo, to three internationally renowned neuroscience facilities. We are looking forward to working with the MRC Cognition and Brain Sciences...
OXFORD, UNITED KINGDOM (February 08, 2019) – MEGIN, a Croton Healthcare Company, is pleased to announce that the University of Oxford is the first in Europe to acquire the latest technology in functional brain imaging. TRIUX™ neo, a magnetoencephalograph (MEG), is a...
MEGIN CEO Speaks at Neuroscience-20 World Brain Mapping Summit in Argentina BUENOS AIRES, Argentina, Dec. 6, 2018 -- Janne Huhtala, CEO of MEGIN, a manufacturer of magnetoencephalography (MEG) technology for functional brain imaging, spoke about the future innovation...
Click here to see the entire original article. "MEMPHIS, Tenn., Sept. 26, 2018/PRNewswire/ --MEGIN announced today Le Bonheur Children's Hospital is the first hospital in the world to install TRIUX™ neo, the next generation of magnetoencephalography (MEG) technology...
It's a new year and a fresh start. We announced a new commercial name for the MEG business at the American Epilepsy Society (AES) Annual Meeting in Washington D.C. in December 2017, and we want to thank those of you who had the opportunity to visit our booth there....
After a busy annual meeting of the American Epilepsy Society, MEGIN is ready to enter a new era of magnetoencephalography (MEG). As before, we are backed by Elekta but now empowered by our own, independent business brand fully focused on MEG.
MEGIN is exhibiting at the annual meeting of American Epilepsy Society in Washington, D.C., from 2–4 December where we have news on TRIUX™ neo. See us at booth #1207. Read more: http://bit.ly/2kg6BtP
Contact us to learn more about MEGIN and our products, or to send us suggestions.
+358 9 756 2400